Download PDF
Digestive Disease Interventions 2020; 04(04): 373-381
DOI: 10.1055/s-0040-1721404
Review Article

Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies

Johannes Uhlig
1   Department of Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany
,
Lorenz Biggemann
1   Department of Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany
,
Amar Sheth
2   Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, United States
,
Rohini Sharma
3   Department of Surgery and Cancer, Imperial College London, London, United Kingdom
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In recent years, systemic cancer treatment has been revolutionized with the advent of immunotherapy, which utilizes the body's immune system to target cancer cells and results in unique and novel imaging patterns of cancer response and therapy-associated toxicities. Hyperprogression is defined as a rapid tumor progression after treatment initiation. In contrast, pseudoprogression is defined as a tumor response after an initial increase in tumor burden, or appearance of new tumor lesions, and observed in <10% of patients undergoing PD-1/PD-L1 immunotherapy. Since traditional radiological strategies might not fully capture tumor response of patients receiving immunotherapy, several efforts have been made to better quantify specific immuno-oncological imaging patterns, including immune-related response criteria, immune-related RECIST, immunotherapy RECIST, and modified RECIST. These criteria account for potential pseudoprogression, and thus may prevent preemptive immunotherapy cessation. Immunotherapy is also associated with specific immune-related adverse events, including colitis (8–22% of patients), hypophysitis (8–13%), pneumonitis (<4%), lymphadenopathy (5–7%), hepatitis (1–7%), and pancreatitis (2%). Quantification of imaging studies using radiomic features has shown promising results in immuno-oncology, including prediction of individual patient's treatment response and survival, as well as characterization of tumoral expression of immunotherapy-relevant targets.

Keywords

immunotherapy - imaging - radiomics


Publication History

Received: 12 July 2020

Accepted: 01 October 2020

Article published online:
19 November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 El-Khoueiry AB, Sangro B, Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389 (10088): 2492-2502
    CrossrefPubMedGoogle Scholar
  • 2 Yau T, Park JW, Finn RS. et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019; 30: v874-v875
    CrossrefPubMedGoogle Scholar
  • 3 Zhu AX, Finn RS, Edeline J. et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19 (07) 940-952
    CrossrefPubMedGoogle Scholar
  • 4 Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19 (19) 5300-5309
    CrossrefPubMedGoogle Scholar
  • 5 Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol 2012; 23 (Suppl. 08) viii15–21
    PubMedGoogle Scholar
  • 6 Fashoyin-Aje L, Donoghue M, Chen H. et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 2019; 24 (01) 103-109
    CrossrefPubMedGoogle Scholar
  • 7 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480 (7378): 480-489
    CrossrefPubMedGoogle Scholar
  • 8 Wolchok JD, Hoos A, O'Day S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15 (23) 7412-7420
    CrossrefPubMedGoogle Scholar
  • 9 Suzuki C, Jacobsson H, Hatschek T. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008; 28 (02) 329-344
    CrossrefPubMedGoogle Scholar
  • 10 van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010; 20 (06) 1456-1467
    CrossrefPubMedGoogle Scholar
  • 11 Lo Russo G, Moro M, Sommariva M. et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res 2019; 25 (03) 989-999
    CrossrefPubMedGoogle Scholar
  • 12 Curiel TJ, Coukos G, Zou L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10 (09) 942-949
    CrossrefPubMedGoogle Scholar
  • 13 Arlauckas SP, Garris CS, Kohler RH. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 2017; 9 (389) 3604
    CrossrefPubMedGoogle Scholar
  • 14 Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125 (09) 3356-3364
    CrossrefPubMedGoogle Scholar
  • 15 Ramos RN, Piaggio E, Romano E. Mechanisms of resistance to immune checkpoint antibodies. Handb Exp Pharmacol 2018; 249: 109-128
    CrossrefPubMedGoogle Scholar
  • 16 Matsushita H, Vesely MD, Koboldt DC. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482 (7385): 400-404
    CrossrefPubMedGoogle Scholar
  • 17 Champiat S, Dercle L, Ammari S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23 (08) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 18 Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017; 23 (15) 4242-4250
    CrossrefPubMedGoogle Scholar
  • 19 Saâda-Bouzid E, Defaucheux C, Karabajakian A. et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017; 28 (07) 1605-1611
    CrossrefPubMedGoogle Scholar
  • 20 Wolchok JD, Hamid O, Ribas A. et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol 2015; 33: 3000
    CrossrefPubMedGoogle Scholar
  • 21 Weber JS, D'Angelo SP, Minor D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16 (04) 375-384
    CrossrefPubMedGoogle Scholar
  • 22 Haddad R, Concha-Benavente F, Blumenschein Jr G. et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial. Cancer 2019; 125 (18) 3208-3218
    CrossrefPubMedGoogle Scholar
  • 23 Nishino M, Giobbie-Hurder A, Manos MP. et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res 2017; 23 (16) 4671-4679
    CrossrefPubMedGoogle Scholar
  • 24 Di Giacomo AM, Danielli R, Guidoboni M. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58 (08) 1297-1306
    CrossrefPubMedGoogle Scholar
  • 25 Lee JH, Long GV, Boyd S. et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 2017; 28 (05) 1130-1136
    CrossrefPubMedGoogle Scholar
  • 26 Rocha P, Hardy-Werbin M, Naranjo D. et al. CD103+CD8+ Lymphocytes characterize the immune infiltration in a case with pseudoprogression in squamous NSCLC. J Thorac Oncol 2018; 13 (10) e193-e196
    CrossrefPubMedGoogle Scholar
  • 27 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (01) 207-214
    CrossrefPubMedGoogle Scholar
  • 28 Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (03) 205-216
    CrossrefPubMedGoogle Scholar
  • 29 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedGoogle Scholar
  • 30 Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book 2018; 38: 169-178
    CrossrefPubMedGoogle Scholar
  • 31 Hodi FS, Hwu WJ, Kefford R. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34 (13) 1510-1517
    CrossrefPubMedGoogle Scholar
  • 32 Zhao B, Tan Y, Bell DJ. et al. Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol 2013; 82 (06) 959-968
    CrossrefPubMedGoogle Scholar
  • 33 Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19 (14) 3936-3943
    CrossrefPubMedGoogle Scholar
  • 34 Seymour L, Bogaerts J, Perrone A. et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18 (03) e143-e152
    CrossrefPubMedGoogle Scholar
  • 35 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol 2020; 72 (02) 288-306
    CrossrefPubMedGoogle Scholar
  • 37 Moehler M, Heo J, Lee HC. et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology 2019; 8 (08) 1615817
    CrossrefPubMedGoogle Scholar
  • 38 Weber JS, Hodi FS, Wolchok JD. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35 (07) 785-792
    CrossrefPubMedGoogle Scholar
  • 39 Michot JM, Bigenwald C, Champiat S. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-148
    CrossrefPubMedGoogle Scholar
  • 40 Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care. Radiographics 2017; 37 (05) 1371-1387
    CrossrefPubMedGoogle Scholar
  • 41 Baxi S, Yang A, Gennarelli RL. et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018; 360: k793
    CrossrefPubMedGoogle Scholar
  • 42 Tirumani SH, Ramaiya NH, Keraliya A. et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015; 3 (10) 1185-1192
    CrossrefPubMedGoogle Scholar
  • 43 Boutros C, Tarhini A, Routier E. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13 (08) 473-486
    CrossrefPubMedGoogle Scholar
  • 44 Faje AT, Sullivan R, Lawrence D. et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99 (11) 4078-4085
    CrossrefPubMedGoogle Scholar
  • 45 Min L, Hodi FS, Giobbie-Hurder A. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21 (04) 749-755
    CrossrefPubMedGoogle Scholar
  • 46 Khunger M, Rakshit S, Pasupuleti V. et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017; 152 (02) 271-281
    CrossrefPubMedGoogle Scholar
  • 47 Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011; 197 (06) W992-W1000
    CrossrefPubMedGoogle Scholar
  • 48 Berthod G, Lazor R, Letovanec I. et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012; 30 (17) e156-e159
    CrossrefPubMedGoogle Scholar
  • 49 Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119 (09) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 50 Kim KW, Ramaiya NH, Krajewski KM. et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 2013; 200 (05) W468-74
    PubMedGoogle Scholar
  • 51 Kim KW, Ramaiya NH, Krajewski KM. et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31 (04) 1071-1077
    CrossrefPubMedGoogle Scholar
  • 52 Wolchok JD, Kluger H, Callahan MK. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369 (02) 122-133
    CrossrefPubMedGoogle Scholar
  • 53 Hodi FS, O'Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (08) 711-723
    CrossrefPubMedGoogle Scholar
  • 54 Robert C, Schachter J, Long GV. et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372 (26) 2521-2532
    CrossrefPubMedGoogle Scholar
  • 55 Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book 2018; 38: 13-19
    CrossrefPubMedGoogle Scholar
  • 56 Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 2018; 23 (09) 991-997
    CrossrefPubMedGoogle Scholar
  • 57 Sanjeevaiah A, Kerr T, Beg MS. Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol 2018; 9 (01) 220-224
    CrossrefPubMedGoogle Scholar
  • 58 Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin Gastroenterol Hepatol 2007; 5 (01) 70-74
    CrossrefPubMedGoogle Scholar
  • 59 Friedman CF, Clark V, Raikhel AV. et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst 2016; 109 (04) 109
    PubMedGoogle Scholar
  • 60 Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 76-83
    CrossrefPubMedGoogle Scholar
  • 61 Choi H, Charnsangavej C, de Castro Faria S. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183 (06) 1619-1628
    CrossrefPubMedGoogle Scholar
  • 62 Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014; 2 (01) 40
    CrossrefPubMedGoogle Scholar
  • 63 Lambin P, Rios-Velazquez E, Leijenaar R. et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48 (04) 441-446
    CrossrefPubMedGoogle Scholar
  • 64 Kumar V, Gu Y, Basu S. et al. Radiomics: the process and the challenges. Magn Reson Imaging 2012; 30 (09) 1234-1248
    CrossrefPubMedGoogle Scholar
  • 65 Parmar C, Rios Velazquez E, Leijenaar R. et al. Robust Radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One 2014; 9 (07) e102107
    CrossrefPubMedGoogle Scholar
  • 66 Aerts HJ, Velazquez ER, Leijenaar RT. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5: 4006
    CrossrefPubMedGoogle Scholar
  • 67 Ganeshan B, Abaleke S, Young RC, Chatwin CR, Miles KA. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 2010; 10: 137-143
    CrossrefPubMedGoogle Scholar
  • 68 Petkovska I, Shah SK, McNitt-Gray MF. et al. Pulmonary nodule characterization: a comparison of conventional with quantitative and visual semi-quantitative analyses using contrast enhancement maps. Eur J Radiol 2006; 59 (02) 244-252
    CrossrefPubMedGoogle Scholar
  • 69 Uhlig J, Biggemann L, Nietert MM. et al. Discriminating malignant and benign clinical T1 renal masses on computed tomography: A pragmatic radiomics and machine learning approach. Medicine (Baltimore) 2020; 99 (16) e19725
    CrossrefPubMedGoogle Scholar
  • 70 Basler L, Gabryś HS, Hogan SA. et al. Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition. Clin Cancer Res 2020; 26 (16) 4414-4425
    CrossrefPubMedGoogle Scholar
  • 71 Hectors SJ, Lewis S, Besa C. et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol 2020; 30 (07) 3759-3769
    CrossrefPubMedGoogle Scholar
  • 72 Sun R, Limkin EJ, Vakalopoulou M. et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018; 19 (09) 1180-1191
    CrossrefPubMedGoogle Scholar
  • 73 Trebeschi S, Drago SG, Birkbak NJ. et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol 2019; 30 (06) 998-1004
    CrossrefPubMedGoogle Scholar
  • 74 Chen S, Feng S, Wei J. et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019; 29 (08) 4177-4187
    CrossrefPubMedGoogle Scholar
  • 75 Liao H, Zhang Z, Chen J. et al. Preoperative radiomic approach to evaluate tumor-infiltrating CD8+ T cells in hepatocellular carcinoma patients using contrast-enhanced computed tomography. Ann Surg Oncol 2019; 26 (13) 4537-4547
    CrossrefPubMedGoogle Scholar
  • 76 Mlecnik B, Tosolini M, Kirilovsky A. et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29 (06) 610-618
    CrossrefPubMedGoogle Scholar
  • 77 Balagurunathan Y, Kumar V, Gu Y. et al. Test-retest reproducibility analysis of lung CT image features. J Digit Imaging 2014; 27 (06) 805-823
    CrossrefPubMedGoogle Scholar
  • 78 Balagurunathan Y, Gu Y, Wang H. et al. Reproducibility and prognosis of quantitative features extracted from CT images. Transl Oncol 2014; 7 (01) 72-87
    CrossrefPubMedGoogle Scholar